Immunomedics, Inc. was a big mover last session, as the company saw its shares rise over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $7.74 to $8.91 in the past one-month time frame.

The stock gained after the company reported encouraging interim results from a phase II study on its antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130).

The company has not seen any negative estimate revisions in the past few weeks, but its Zacks Consensus Estimate for the current quarter has moved lower over the past 30 days, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the Biomedical and Genetics industryis Alexion Pharmaceuticals, Inc. , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Immunomedics, Inc. Price

Immunomedics, Inc. Price | Immunomedics, Inc. Quote

Is IMMU going up? Or down? Predict to see what others think: Up or Down

4 Surprising Tech Stocks to Keep an Eye on

Tech stocks have been a major force behind the market’s record highs, but picking the best ones to buy can be tough. There’s a simple way to invest in the success of the entire sector. Zacks has just released a Special Report revealing one thing tech companies literally cannot function without. More importantly, it reveals 4 top stocks set to skyrocket on increasing demand for these devices. I encourage you to get the report now – before the next wave of innovations really takes off.

See Stocks Now>>